Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
The return on assets (ROA) is N/A as of the fiscal period ended Wednesday, December 31, 2025.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -14.44%.
RETURN ON ASSETS (ROA)
N/A
RETURN ON ASSETS (ROA) AVG TTM
-140.48%
RETURN ON ASSETS (ROA) AVG 3Y
-390.49%
RETURN ON ASSETS (ROA) AVG 5Y
-423.69%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
GRI Bio, Inc.
Market Cap
$4.09M
Return on Assets (ROA)
N/A
TTM Avg
-140.48%
3Y Avg
-390.49%
5Y Avg
-423.69%
Market Cap
$4.26M
Return on Assets (ROA)
-94.96%
TTM Avg
-122.01%
3Y Avg
-81.62%
5Y Avg
-58.26%
Market Cap
$4.10M
Return on Assets (ROA)
-649.33%
TTM Avg
-270.27%
3Y Avg
-262.72%
5Y Avg
-194.93%
Market Cap
$4.05M
Return on Assets (ROA)
-181.89%
TTM Avg
-125.13%
3Y Avg
-74.22%
5Y Avg
-63.39%
Market Cap
$4.01M
Return on Assets (ROA)
-194.09%
TTM Avg
-543.36%
3Y Avg
-310.28%
5Y Avg
-256.27%
Market Cap
$4.34M
Return on Assets (ROA)
-173.86%
TTM Avg
-97.65%
3Y Avg
-65.17%
5Y Avg
-52.25%
Market Cap
$4.45M
Return on Assets (ROA)
-43.98%
TTM Avg
7.01%
3Y Avg
2.17%
5Y Avg
-7.32%
Market Cap
$4.50M
Return on Assets (ROA)
-157.28%
TTM Avg
-221.91%
3Y Avg
-169.98%
5Y Avg
-213.74%
Market Cap
$4.64M
Return on Assets (ROA)
-28.02%
TTM Avg
-155.25%
3Y Avg
-160.56%
5Y Avg
-117.99%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GRI Bio, Inc. (GRI) | $4.09M | N/A | -140.48% | -390.49% | -423.69% |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.26M | -94.96% | -122.01% | -81.62% | -58.26% |
| Processa Pharmaceuticals, Inc. (PCSA)vs › | $4.10M | -649.33% | -270.27% | -262.72% | -194.93% |
| Aptevo Therapeutics Inc. (APVO)vs › | $4.05M | -181.89% | -125.13% | -74.22% | -63.39% |
| Ernexa Therapeutics Inc. (ERNA)vs › | $4.01M | -194.09% | -543.36% | -310.28% | -256.27% |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.34M | -173.86% | -97.65% | -65.17% | -52.25% |
| PharmaCyte Biotech, Inc. (PMCB)vs › | $4.45M | -43.98% | 7.01% | 2.17% | -7.32% |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.50M | -157.28% | -221.91% | -169.98% | -213.74% |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.64M | -28.02% | -155.25% | -160.56% | -117.99% |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.77M | -161.71% | -175.21% | -164.83% | -138.13% |
ROA
N/A
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -137.96% |
| 2024-12-31 | -143.00% |
| 2023-12-31 | -441.04% |
| 2022-12-31 | -839.95% |
| 2021-12-31 | -715.14% |
| 2020-12-31 | -265.03% |
| 2019-12-31 | -81.03% |
| 2018-12-31 | -674.66% |
